Sten Verland is founding partner at Sunstone Capital A/S, a major investor in Anergis. He has more than 20 years experience as an international executive, entrepreneur and venture investor in biotech companies as well as pre-clinical and clinical CROs. Dr. Verland holds a M.Sc. in Biology and a Ph.D. in Immunology from the University of Copenhagen. After completing his doctorate, he held a number of academic positions in the field of biomedical research including the position of Assistant Professor in Immunology at the University of Copenhagen. In 1994, Dr. Verland headed a Management Buy-Out of a contract research organization (CRO) specializing in laboratory animal science and non-clinical development. After 4 years as a major shareholder, Dr. Verland merged the company with another CRO thus forming M&B A/S, which was subsequently acquired by Taconic, Inc., New York, in 2000. In 1998, Dr. Verland participated in the foundation of Synarc, Inc., San Francisco, and served for 4½ years as VP, General Manager Europe. During his tenure, Synarc developed from a small start-up clinical service provider into the world's largest central radiology service company dedicated exclusively to global clinical trials. From 2003 to 2007, Dr. Verland operated his own investment company where he co-founded or invested in 7 life science companies and served as non-executive director on 16 Boards.


  • Biopôle Building SC-A
    Route de la Corniche 4
    CH-1066 Epalinges
  • Email:

This website uses cookies to ensure you get the best experience on our website.